🔎 Trials Near Me

Utama › Kanser Ovari › Florida › Sarasota

Kajian klinikal Kanser Ovari di Sarasota, FL

16 kajian untuk Kanser Ovari sedang mencari peserta di lokasi dalam dan sekitar Sarasota (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

Mengambil pesertaKajian pemerhatian
  • Sarasota Memorial Health Care System, Sarasota
Umur 18 ke atas · Wanita · Dikemas kini 29 Sep 2026 · NCT05051722

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

Mengambil pesertaFasa 1/2
  • Florida Cancer Specialists, Sarasota
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT06799065

Study of AVZO-021 in Patients With Advanced Solid Tumors

Mengambil pesertaFasa 1/2
  • Avenzo Therapeutics Recruiting Site, Sarasota
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT05867251

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Mengambil pesertaFasa 1/2
  • Florida Cancer Specialists, Sarasota
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06128551

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Mengambil pesertaFasa 3
  • Sarasota Memorial Health Care System, Sarasota
Umur 18 ke atas · Wanita · Dikemas kini 15 Sep 2026 · NCT07214779

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Mengambil pesertaFasa 3
  • Sarasota Memorial Healthcare System, Sarasota
Umur 18 ke atas · Wanita · Dikemas kini 26 Ogo 2026 · NCT05281471

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

Mengambil pesertaFasa 1
  • SCRI - Florida Cancer Specialists, Sarasota
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Ogo 2026 · NCT07470853

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Mengambil peserta
  • Florida Cancer Specialists - Sarasota, Sarasota
  • Intercoastal Medical Group - Cattleridge II, Sarasota
  • First Physicians Group - Gastroenterology Obesity Medicine, Sarasota
  • dan 7 lagi
Umur 35 hingga 50 · Wanita · Dikemas kini 7 Ogo 2026 · NCT04251052

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Mengambil pesertaFasa 1/2
  • Florida Cancer Specialists, Sarasota
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Jul 2026 · NCT04657068

A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer

Mengambil pesertaFasa 1
  • Florida Cancer Specialists & Research Institute, Sarasota
Umur 18 ke atas · Wanita · Dikemas kini 6 Jul 2026 · NCT07226427

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

Mengambil pesertaFasa 1/2
  • Florida Cancer Specialists, Sarasota
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Jun 2026 · NCT05377996

A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

Mengambil pesertaFasa 1
  • Florida Cancer Specialists, Sarasota
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Jan 2026 · NCT06234423

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Mengambil pesertaFasa 1
  • Dren Investigational Site, Sarasota
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Jan 2026 · NCT06999187

Kajian Kanser Ovari di bandar lain

Kajian lain di Sarasota

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.